Materias dentro de su búsqueda.
Mostrando 5,641 - 5,660 Resultados de 5,950 Para Buscar 'Hanussen~', tiempo de consulta: 1.91s Limitar resultados
  1. 5641
    “…The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga(®)), to submit evidence for the clinical and cost effectiveness of AA in combination with prednisone/prednisolone (AAP) compared with watchful waiting (i.e. best supportive care [BSC]) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
  2. 5642
    “…Segal-Maurer, Gilead Sciences: Consultant, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Janssen Therapeutics: Speaker’s Bureau, Speaker honorarium; D. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study
  3. 5643
    “…Ramilo, Abbvie: Board Member, Consulting fee; Regeneron: Board Member, Consulting fee; Janssen: Board Member and Investigator, Consulting fee and Research grant; NIH: Grant Investigator, Research grant; A. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio
  4. 5644
    “…Ramilo, Abbvie: Board Member, Consulting fee; Regeneron: Board Member, Consulting fee; Janssen: Board Member and Investigator, Consulting fee and Research grant; NIH: Grant Investigator, Research grant; A. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Enterovirus Infection in Young Infants: Prevalence, Clinical and Laboratory Characteristics in Columbus, Ohio
  5. 5645
    “…Fowler Jr., Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect: Consultant, Consulting fee; NIH, Basilea, MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius: Grant Investigator, Research grant; Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm: Consultant, Consulting fee; UpToDate: author on several chapters, Royalties…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Complicated Staphylococcus aureus Bacteremia (SAB) Is Associated with Genetic Variation in GLS2
  6. 5646
    “…Merck Sharpe and Dome: Investigator, Grant recipient. Janssen Pharmacueticals: Investigator, Grant recipient. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    733. Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults
  7. 5647
    “…DISCLOSURES: J. R. Johnson, Crucell/Janssen: Consultant, Consulting fee. Allergan: Grant Investigator, Research support. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    656. E. coli Clone Sharing and Persistence Within Households (HHs) in Relation to Fluoroquinolone (FQ) Resistance and ST131 Status
  8. 5648
    “…Gilead: Grant Investigator, Research grant. Janssen: Grant Investigator, Research grant. Merck & Co.: Grant Investigator, Research grant. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
  9. 5649
    “…[Image: see text] DISCLOSURES: Octavio Ramilo, MD, Bill & Melinda Gates Foundation: Research Grant; Janssen: Research Grant; Merck: Advisory Board; NIH: Research Grant; Ohio Children’s Hospital Association (OCHA): Research Grant; Pfizer: Advisory Board, Consultant, Lectures; Sanofi/Medimmune: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    79. Mucosal Interferon (IFN) Responses in Infants with Respiratory Syncytial Virus (RSV) Infection to Inform Live Attenuated Vaccine (LAV) Development
  10. 5650
    “…FUNDING: ZonMw, H-TEAM, Internal GGD research funds, Aidsfonds, Stichting AmsterdamDiner Foundation, Gilead Sciences, Janssen Pharmaceutica, M A C AIDS Fund, and ViiV Healthcare.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Changes in mental health and drug use among men who have sex with men using daily and event-driven pre-exposure prophylaxis: Results from a prospective demonstration project in Amsterdam, the Netherlands
  11. 5651
    “…FUNDING: ZonMw, H-TEAM, RIVM, GGD research funds, Aidsfonds, Amsterdam Diner Foundation, Gilead Sciences, Gilead Sciences Europe Ltd, Janssen Pharmaceuticals, MAC AIDS Fund, ViiV Healthcare.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Understanding pre-exposure prophylaxis (PrEP) regimen use: Switching and discontinuing daily and event-driven PrEP among men who have sex with men
  12. 5652
    “…[Image: see text] DISCLOSURES: Jenny Schulz, PhD, Eiger Biopharmaceuticals (Other Financial or Material Support, Editorial support) Paul Kwo, MD, Abbvie (Advisor or Review Panel member)Alios (Advisor or Review Panel member)Assembly Biosciences (Research Grant or Support)Eiger (Research Grant or Support)Gilead Sciences (Advisor or Review Panel member)Janssen (Other Financial or Material Support, Data and Safety Monitoring Board)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1131. Point-of-Care Interactive Decision Support Tool Demonstrates Discordance Between Healthcare Practitioner Approaches and AASLD Guideline Recommendations in the Management of HBV Infection
  13. 5653
    “…Safety appeared to be similar to that in other phase 3 trials of Covid-19 vaccines. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
  14. 5654
    “…PRIMARY FUNDING SOURCE: Janssen.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    When Can We Lift Non‐Pharmaceutical Interventions with the Availability of COVID‐19 Vaccine in the United States?
  15. 5655
    “…As of 23 September 2021, four vaccines, namely, Comirnaty, COVID-19 vaccine Janssen, Spikevax, and Vaxzevria, have received the European Medicines Agency’s (EMA) approval, and around thirty are under the phase three clinical trial with emergency authorization by the vaccine-developing country-specific National Regulatory Authority (NRA). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
  16. 5656
    “…[Image: see text] [Image: see text] DISCLOSURES: Naoki Hasegawa, MD, PhD, Insmed Incorporated (Consultant, Scientific Research Study Investigator)Janssen Pharmaceuticals Inc (Consultant, Scientific Research Study Investigator) Kozo Morimoto, MD, Insmed Incorporated (Consultant) Ping Wang, PhD, Insmed Incorporated (Employee) Lu Zhang, PhD, Panalgo (Employee, Other Financial or Material Support, Lu Zhang is an employee of Panalgo which provides the analytic platform Instant Health Data that is used by Insmed) Mariam Hassan, PhD, B. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1396. The Incremental Hospitalization Burden Associated with Nontuberculous Mycobacterial Lung Disease(NTMLD) among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Japan
  17. 5657
    “…DISCLOSURES: Stephen R. Walsh, MDCM, Janssen Vaccines (Scientific Research Study Investigator)Regeneron (Scientific Research Study Investigator)Sanofi Pasteur (Scientific Research Study Investigator) Matthew Cheng, MD, GEn1E Lifesciences (Advisor or Review Panel member)Kanvas Biosciences (Board Member, Shareholder)nplex biosciences (Advisor or Review Panel member) Sanjat Kanjilal, MD, MPH, GlaskoSmithKline (Advisor or Review Panel member) Nicolas C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant
  18. 5658
    “…DISCLOSURES: Carsten Utoft Niemann, PhD MD, Abbvie (Grant/Research Support, Advisor or Review Panel member)Astra Zeneca (Grant/Research Support, Advisor or Review Panel member, teaching)CSL Behring (Consultant)Genmab (Grant/Research Support)Gilead (Grant/Research Support)Janssen (Grant/Research Support, teaching)Novo Nordisk Foundation (Grant/Research Support)Roche (Grant/Research Support)Sunesis (Grant/Research Support)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    29. Sustained Recovery in Patients Admitted to Hospital With COVID-19
  19. 5659
    “…Main funding source(s): Janssen Pharmaceuticals…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiovascular outcomes in hospitalized patients with COVID-19 and history of cancer: a CORONA-VTE analysis
  20. 5660
    “…Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Herramientas de búsqueda: RSS